Minoryx Therapeutics S.L.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Apr 2035
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Feb 22 to 28, 2027 · next Feb 22
- 1 fee due Sep 26, 2027The maintenance fee for 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3- thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease (US 11,938,122) comes due Sep 26, 2027. Unpaid by Mar 27, 2028, it lapses early.
- 1 fee due Oct 16, 2027The maintenance fee for 5-[[4-[2-[5-(1-Hydroxyethyl)PYRIDIN-2-YL]ETHOXY]PHENYL]METHYL]-1,3-Thiazolidine-2,4-Dione and Its Salts for Use in the Treatment of Mitochondrial Diseases (US 11,957,670) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 10 of 10
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,782,395 | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders In force · USPTO record | In force | USPTO record | |
| US 10,179,126 | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders In force · USPTO record | In force | USPTO record | |
| US 11,938,122 | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3- thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease In force · USPTO record | In force | USPTO record | |
| US 11,124,505 | Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof In force · USPTO record | In force | USPTO record | |
| US 11,731,963 | Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]-methyl]-2,4-thiazolidinedione and salts thereof In force · USPTO record | In force | USPTO record | |
| US 11,739,072 | Heteroaryl compounds and their use In force · USPTO record | In force | USPTO record | |
| US 11,174,242 | Heteroaryl compounds and their use In force · USPTO record | In force | USPTO record | |
| US 11,440,898 | Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase In force · USPTO record | In force | USPTO record | |
| US 12,673,048 | Method of Administering a Therapeutically Effective Amount of 5-[[4-[2-[5-(1-Hydroxyethyl)PYRIDIN-2-YL]ETHOXY]PHENYL]METHYL]-1,3-Thiazolidine-2,4-Dione In force · High confidence | In force | High confidence | |
| US 11,957,670 | 5-[[4-[2-[5-(1-Hydroxyethyl)PYRIDIN-2-YL]ETHOXY]PHENYL]METHYL]-1,3-Thiazolidine-2,4-Dione and Its Salts for Use in the Treatment of Mitochondrial Diseases In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 1 abandoned · 3 no status recorded